A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
The purpose of this study is to compare concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin).
Participants will be randomly assigned to receive radiation plus either cisplatin or nivolumab.
- IRB Number: 1912360365
- Research Study Identifier: NCT03952585
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required